STX Insider Trading (Shield Therapeutics plc (STX.L))

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): £130,000

Insider Selling (Last 12 Months): GBX 0

Shield Therapeutics plc (STX.L) Insider Trading History Chart

Shield Therapeutics plc (STX.L) Share Price & Price History

GBX 54.50

▲ +3 (5.83%)

As of 02/25/2021 01:54 PM ET

Days: 30 | 90 | 365

This undiscovered CBD play is on the verge of disrupting the industry

From Emerging Markets Consulting | Ad

With recent health Canada approval they are poised to explode

Shield Therapeutics plc (STX.L) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
1/19/2021	Tim Watts	Insider	Buy	100,000	GBX 60	£60,000
12/11/2020	Tim Watts	Insider	Buy	100,000	GBX 70	£70,000
4/25/2019	Mark Sampson	Insider	Buy	22,042	GBX 91	£20,058.22
4/16/2019	James M Karis	Insider	Buy	4,000	GBX 81	£3,240
9/21/2018	Carl Sterritt	Insider	Buy	88,235	GBX 34	£29,999.90

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Today's Range

Now: GBX 54.50

54.50

50 Day Range

MA: GBX 54.45

48.50

62.80

52 Week Range

Now: GBX 54.50

39.10

153

Volume

149,242 shs

Average Volume

1,058,462 shs

Market Capitalization

£64.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Shield Therapeutics plc (STX.L)?

Shield Therapeutics plc (STX.L)'s top insider shareholders include:

James M Karis (Insider)
Mark Sampson (Insider)
Tim Watts (Insider)